In vitro production of dendritic cells from human blood monocytes for therapeutic use

Journal of Hematotherapy and Stem Cell Research

Volumn 10, Issue 4, 2001, Pages 553-567

  Garderet, L ^a   Cao, H ^a   Salamero, J ^b   Verge V ^a   Tisserand, E ^a   Scholl, S ^b   Gorin, N C ^a   Lopez, M ^a  

^a INSERM   (France)

^b INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; APHERESIS; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IMMUNOTHERAPY; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL;

EID: 0034890558     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/15258160152509163     Document Type: Article

References (40)

1. Dendritic cells and the control of immunity
2. Antigen uptake and presentation by dendritic leukocytes
3. Efficient presentation soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α
4. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumour immunity
5. Peptidepulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity
6. Vaccination of patients with B-cell lymphoma using autologous antigenpulsed dendritic cells
7. + cells isolated from G-CSF mobilized blood to differentiate in vitro into potent antigen presenting cells
8. Generation of mature dendritic cells from human blood-an improved method with special regard to clinic applicability
9. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application
10. Improved methods for the generation of dendritic cells from nonproliferation progenitors in human blood
11. Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy
12. Adherent free generation of functional dendritic cells from purified blood monocytes in view of potential clinical use
13. In vitro generation of dendritic cells from human blood monocytes of healthy donors and patients in experimental conditions compatible for their use in cell therapy
14. Adoptive immunotherapy with activated macrophages grown in vitro from blood monocytes in cancer patients: A pilot study
15. Autologous lymphocytes prevent the death of monocytes in cultures and promote, as do GM-CSF, IL-3 and M-CSF, their differentiation into macrophages
16. Intracellular pathway for the generation of functional MHC class II peptide complexes in immature human dendritic cells
17. Human resident langerhans cells display a lysosomal compartment enriched in MHC class II
18. Developmental regulation of MHC class II transport in mouse dendritic cells
19. GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells
20. A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells
21. CD1a molecules traffic through the early recycling endosomal pathway in human Langerhans cells
22. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
23. Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer
24. Dendritic cells injected via different routes induce immunity in cancer patients
25. Vaccination with Mage-3A1 peptidepulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
26. + hematopoietic progenitor
27. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma
28. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma. A feasibility study
29. Dendritic cell-based idiotype vaccination in post transplant multiple myeloma
30. Efficacy of idiotype-pulsed autologous dendritic cells for treatment of advanced refractory multiple myeloma
31. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: Immunological and clinical aspects
32. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease
33. Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients
34. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells
35. + blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer
36. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells
37. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
38. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells
39. A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
40. Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells